Well done_老虎社区_美港股上老虎

2021-06-08

Well done

6 Million Americans Are Rooting for Monday's Big Stock Market Winner<blockquote>600万美国人支持周一股市大赢家</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":117657812,"tweetId":"117657812","gmtCreate":1623140204236,"gmtModify":1634036530175,"author":{"id":3576631475134774,"idStr":"3576631475134774","authorId":3576631475134774,"authorIdStr":"3576631475134774","name":"Yoda0603","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Well done&nbsp;</body></html>","htmlText":"<html><head></head><body>Well done&nbsp;</body></html>","text":"Well done","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/117657812","repostId":1170180025,"repostType":4,"repost":{"id":"1170180025","kind":"news","pubTimestamp":1623137843,"share":"https://www.laohu8.com/m/news/1170180025?lang=zh_CN&edition=full","pubTime":"2021-06-08 15:37","market":"us","language":"en","title":"6 Million Americans Are Rooting for Monday's Big Stock Market Winner<blockquote>600万美国人支持周一股市大赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1170180025","media":"Motley Fool","summary":"It's not just about money. This company could change millions of lives for the better.\n\nIt's not eve","content":" It's not just about money. This company could change millions of lives for the better. It's not every day that a news event involving the stock market has the potential to change the lives of millions of people for the better. But that's what happened today, and although the decision involves some controversy, the latest approval from the U.S. Food and Drug Administration paves the way for a potential breakthrough for the more than 6 million Americans who suffer from a terrible and debilitating illness.<blockquote>这不仅仅是钱的问题。这家公司可以让数百万人的生活变得更好。并不是每天都有涉及股市的新闻事件有可能让数百万人的生活变得更好。但这就是今天发生的事情，尽管这个决定涉及一些争议，但美国的最新批准。美国食品药品监督管理局为600多万患有可怕和使人虚弱的疾病的美国人的潜在突破铺平了道路。</blockquote> To be clear, the entire stock market didn't celebrate the news. TheDow Jones Industrial Average&nbsp;andS&amp;P 500were both down on the day, although gains for theNasdaq Composite&nbsp;were nice to see.<blockquote>需要明确的是，整个股市并没有庆祝这个消息。The道琼斯工业平均指数和标普500当天均下跌，尽管上涨纳斯达克复合材料很高兴见到你。</blockquote> <img src=\"https://static.tigerbbs.com/181bcc06eb97d19baf436292a1eb2331\" tg-width=\"793\" tg-height=\"292\">Indeed, the Nasdaq's gain came in part from the performance of the high-flying stock in question.Biogen(NASDAQ:BIIB)surged higher by more than 38% on Monday, and the gains came on hopes that the company might finally be able to solve the problem of Alzheimer's disease once and for all.<blockquote>事实上，纳斯达克的收益部分来自于相关股票的表现。Biogen（纳斯达克：BIIB）周一大涨逾38%，上涨源于该公司最终可能能够一劳永逸地解决阿尔茨海默病问题的希望。</blockquote> An approval for Biogen<blockquote>Biogen的批准</blockquote> Biogen's stock soared after a long trading halt that lasted nearly three hours. At noon EDT,Biogen issued a press releasethat announced the FDA's accelerated approval of its aducanumab-avwa treatment for Alzheimer's disease. Using the marketing name Aduhelm for the drug, Biogen claimed the status as having the first and only Alzheimer's treatment addressing what it called \"a defining pathology of the disease\" by reducing amyloid beta plaque levels in patients' brains.<blockquote>百健(Biogen)的股价在持续近三个小时的长时间停牌后飙升。美国东部时间中午，百健(Biogen)发布新闻稿，宣布FDA加速批准其aducanumab-avwa治疗阿尔茨海默病的药物。百健(Biogen)使用该药物的营销名称Aduhelm，声称该药物是第一种也是唯一一种通过降低患者大脑中β淀粉样蛋白斑块水平来解决其所谓的“该疾病的定义病理学”的阿尔茨海默病治疗方法。</blockquote> Biogen said that the FDA issued the accelerated approval based on clinical trial data demonstrating plaque reduction. It'll be up to continuing studies to verify that success in fighting amyloid beta plaque will actually reduce the rate of clinical decline that Alzheimer's disease patients suffer.<blockquote>Biogen表示，FDA发布加速批准是基于临床试验数据证明斑块减少。这将取决于持续的研究来验证成功对抗淀粉样β斑块实际上会降低阿尔茨海默病患者的临床衰退率。</blockquote> CEO Michel Vounatsos calling the approval a \"historic moment\" and celebrated the decade-long work of numerous researchers. Officials atEisai(OTC:ESALY), which has worked together with Biogen on the treatment, were similarly pleased. Eisai stock jumped as much as 70% in over-the-counter trading.<blockquote>首席执行官Michel Vounatsos称这一批准是一个“历史性时刻”，并庆祝了众多研究人员长达十年的工作。官员在卫材（OTC：ESALY）与百健（Biogen）合作进行治疗，也同样感到高兴。卫材股价在场外交易中上涨了70%。</blockquote> Why Biogen's win is controversial<blockquote>为什么百健(Biogen)的胜利存在争议</blockquote> Yet others remain skeptical about Biogen's victory. Although the company has done a good job of showing the direct impact of the treatment on amyloid protein formation, making the further link to demonstrate actual improvement in Alzheimer's symptoms like cognitive ability has been more elusive. In fact,past trials have specifically failedto establish statistically significant benefits.<blockquote>然而，其他人仍然对百健的胜利持怀疑态度。尽管该公司在展示治疗对淀粉样蛋白形成的直接影响方面做得很好，但进一步证明认知能力等阿尔茨海默氏症症状的实际改善却更加难以捉摸。事实上，过去的试验未能确定统计学上显著的益处。</blockquote> Also unusual is the extent of disagreement among researchers in the field.A panel of independent experts wasn't convincedwhen presented with Aduhelm's results that the treatment could directly improve symptoms.<blockquote>同样不寻常的是该领域研究人员之间的分歧程度。当看到Aduhelm的结果时，一个独立专家小组并不相信这种治疗可以直接改善症状。</blockquote> Nevertheless, Biogen can expect sales of Aduhelm to be brisk. With the only approved treatment on the market, Biogen will have many medical professionals looking to try it even if they're skeptical about its eventual impact. That will inevitably produce billions of dollars in revenue for Biogen while allowing the company to continue collecting data on any positive impacts of the treatment on patients.<blockquote>尽管如此，Biogen预计Aduhelm的销售将会很活跃。作为市场上唯一被批准的治疗方法，Biogen将有许多医疗专业人士寻求尝试它，即使他们对其最终影响持怀疑态度。这将不可避免地为百健（Biogen）带来数十亿美元的收入，同时使该公司能够继续收集有关治疗对患者的任何积极影响的数据。</blockquote> Hoping for a cure<blockquote>希望找到治愈方法</blockquote> It's precisely because so much is on the line for so many people that Biogen's Alzheimer's treatment generates such strong emotion. Nevertheless, everyone has to be hoping that Aduhelm will be able to prove itself once and for all and start providing relief for those who suffer from the disease.<blockquote>正是因为如此多的人面临如此多的风险，Biogen的阿尔茨海默氏症治疗产生了如此强烈的情感。然而，每个人都希望Aduhelm能够一劳永逸地证明自己，并开始为那些患有这种疾病的人提供救济。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>6 Million Americans Are Rooting for Monday's Big Stock Market Winner<blockquote>600万美国人支持周一股市大赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n6 Million Americans Are Rooting for Monday's Big Stock Market Winner<blockquote>600万美国人支持周一股市大赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-06-08 15:37\n\n</h4>\n</header>\n<article>\n It's not just about money. This company could change millions of lives for the better. It's not every day that a news event involving the stock market has the potential to change the lives of millions of people for the better. But that's what happened today, and although the decision involves some controversy, the latest approval from the U.S. Food and Drug Administration paves the way for a potential breakthrough for the more than 6 million Americans who suffer from a terrible and debilitating illness.<blockquote>这不仅仅是钱的问题。这家公司可以让数百万人的生活变得更好。并不是每天都有涉及股市的新闻事件有可能让数百万人的生活变得更好。但这就是今天发生的事情，尽管这个决定涉及一些争议，但美国的最新批准。美国食品药品监督管理局为600多万患有可怕和使人虚弱的疾病的美国人的潜在突破铺平了道路。</blockquote> To be clear, the entire stock market didn't celebrate the news. TheDow Jones Industrial Average&nbsp;andS&amp;P 500were both down on the day, although gains for theNasdaq Composite&nbsp;were nice to see.<blockquote>需要明确的是，整个股市并没有庆祝这个消息。The道琼斯工业平均指数和标普500当天均下跌，尽管上涨纳斯达克复合材料很高兴见到你。</blockquote> <img src=\"https://static.tigerbbs.com/181bcc06eb97d19baf436292a1eb2331\" tg-width=\"793\" tg-height=\"292\">Indeed, the Nasdaq's gain came in part from the performance of the high-flying stock in question.Biogen(NASDAQ:BIIB)surged higher by more than 38% on Monday, and the gains came on hopes that the company might finally be able to solve the problem of Alzheimer's disease once and for all.<blockquote>事实上，纳斯达克的收益部分来自于相关股票的表现。Biogen（纳斯达克：BIIB）周一大涨逾38%，上涨源于该公司最终可能能够一劳永逸地解决阿尔茨海默病问题的希望。</blockquote> An approval for Biogen<blockquote>Biogen的批准</blockquote> Biogen's stock soared after a long trading halt that lasted nearly three hours. At noon EDT,Biogen issued a press releasethat announced the FDA's accelerated approval of its aducanumab-avwa treatment for Alzheimer's disease. Using the marketing name Aduhelm for the drug, Biogen claimed the status as having the first and only Alzheimer's treatment addressing what it called \"a defining pathology of the disease\" by reducing amyloid beta plaque levels in patients' brains.<blockquote>百健(Biogen)的股价在持续近三个小时的长时间停牌后飙升。美国东部时间中午，百健(Biogen)发布新闻稿，宣布FDA加速批准其aducanumab-avwa治疗阿尔茨海默病的药物。百健(Biogen)使用该药物的营销名称Aduhelm，声称该药物是第一种也是唯一一种通过降低患者大脑中β淀粉样蛋白斑块水平来解决其所谓的“该疾病的定义病理学”的阿尔茨海默病治疗方法。</blockquote> Biogen said that the FDA issued the accelerated approval based on clinical trial data demonstrating plaque reduction. It'll be up to continuing studies to verify that success in fighting amyloid beta plaque will actually reduce the rate of clinical decline that Alzheimer's disease patients suffer.<blockquote>Biogen表示，FDA发布加速批准是基于临床试验数据证明斑块减少。这将取决于持续的研究来验证成功对抗淀粉样β斑块实际上会降低阿尔茨海默病患者的临床衰退率。</blockquote> CEO Michel Vounatsos calling the approval a \"historic moment\" and celebrated the decade-long work of numerous researchers. Officials atEisai(OTC:ESALY), which has worked together with Biogen on the treatment, were similarly pleased. Eisai stock jumped as much as 70% in over-the-counter trading.<blockquote>首席执行官Michel Vounatsos称这一批准是一个“历史性时刻”，并庆祝了众多研究人员长达十年的工作。官员在卫材（OTC：ESALY）与百健（Biogen）合作进行治疗，也同样感到高兴。卫材股价在场外交易中上涨了70%。</blockquote> Why Biogen's win is controversial<blockquote>为什么百健(Biogen)的胜利存在争议</blockquote> Yet others remain skeptical about Biogen's victory. Although the company has done a good job of showing the direct impact of the treatment on amyloid protein formation, making the further link to demonstrate actual improvement in Alzheimer's symptoms like cognitive ability has been more elusive. In fact,past trials have specifically failedto establish statistically significant benefits.<blockquote>然而，其他人仍然对百健的胜利持怀疑态度。尽管该公司在展示治疗对淀粉样蛋白形成的直接影响方面做得很好，但进一步证明认知能力等阿尔茨海默氏症症状的实际改善却更加难以捉摸。事实上，过去的试验未能确定统计学上显著的益处。</blockquote> Also unusual is the extent of disagreement among researchers in the field.A panel of independent experts wasn't convincedwhen presented with Aduhelm's results that the treatment could directly improve symptoms.<blockquote>同样不寻常的是该领域研究人员之间的分歧程度。当看到Aduhelm的结果时，一个独立专家小组并不相信这种治疗可以直接改善症状。</blockquote> Nevertheless, Biogen can expect sales of Aduhelm to be brisk. With the only approved treatment on the market, Biogen will have many medical professionals looking to try it even if they're skeptical about its eventual impact. That will inevitably produce billions of dollars in revenue for Biogen while allowing the company to continue collecting data on any positive impacts of the treatment on patients.<blockquote>尽管如此，Biogen预计Aduhelm的销售将会很活跃。作为市场上唯一被批准的治疗方法，Biogen将有许多医疗专业人士寻求尝试它，即使他们对其最终影响持怀疑态度。这将不可避免地为百健（Biogen）带来数十亿美元的收入，同时使该公司能够继续收集有关治疗对患者的任何积极影响的数据。</blockquote> Hoping for a cure<blockquote>希望找到治愈方法</blockquote> It's precisely because so much is on the line for so many people that Biogen's Alzheimer's treatment generates such strong emotion. Nevertheless, everyone has to be hoping that Aduhelm will be able to prove itself once and for all and start providing relief for those who suffer from the disease.<blockquote>正是因为如此多的人面临如此多的风险，Biogen的阿尔茨海默氏症治疗产生了如此强烈的情感。然而，每个人都希望Aduhelm能够一劳永逸地证明自己，并开始为那些患有这种疾病的人提供救济。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/06/07/6-million-americans-are-rooting-for-mondays-big-st/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.fool.com/investing/2021/06/07/6-million-americans-are-rooting-for-mondays-big-st/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170180025","content_text":"It's not just about money. This company could change millions of lives for the better.\n\nIt's not every day that a news event involving the stock market has the potential to change the lives of millions of people for the better. But that's what happened today, and although the decision involves some controversy, the latest approval from the U.S. Food and Drug Administration paves the way for a potential breakthrough for the more than 6 million Americans who suffer from a terrible and debilitating illness.\nTo be clear, the entire stock market didn't celebrate the news. TheDow Jones Industrial Average andS&P 500were both down on the day, although gains for theNasdaq Composite were nice to see.\nIndeed, the Nasdaq's gain came in part from the performance of the high-flying stock in question.Biogen(NASDAQ:BIIB)surged higher by more than 38% on Monday, and the gains came on hopes that the company might finally be able to solve the problem of Alzheimer's disease once and for all.\nAn approval for Biogen\nBiogen's stock soared after a long trading halt that lasted nearly three hours. At noon EDT,Biogen issued a press releasethat announced the FDA's accelerated approval of its aducanumab-avwa treatment for Alzheimer's disease. Using the marketing name Aduhelm for the drug, Biogen claimed the status as having the first and only Alzheimer's treatment addressing what it called \"a defining pathology of the disease\" by reducing amyloid beta plaque levels in patients' brains.\nBiogen said that the FDA issued the accelerated approval based on clinical trial data demonstrating plaque reduction. It'll be up to continuing studies to verify that success in fighting amyloid beta plaque will actually reduce the rate of clinical decline that Alzheimer's disease patients suffer.\nCEO Michel Vounatsos calling the approval a \"historic moment\" and celebrated the decade-long work of numerous researchers. Officials atEisai(OTC:ESALY), which has worked together with Biogen on the treatment, were similarly pleased. Eisai stock jumped as much as 70% in over-the-counter trading.\nWhy Biogen's win is controversial\nYet others remain skeptical about Biogen's victory. Although the company has done a good job of showing the direct impact of the treatment on amyloid protein formation, making the further link to demonstrate actual improvement in Alzheimer's symptoms like cognitive ability has been more elusive. In fact,past trials have specifically failedto establish statistically significant benefits.\nAlso unusual is the extent of disagreement among researchers in the field.A panel of independent experts wasn't convincedwhen presented with Aduhelm's results that the treatment could directly improve symptoms.\nNevertheless, Biogen can expect sales of Aduhelm to be brisk. With the only approved treatment on the market, Biogen will have many medical professionals looking to try it even if they're skeptical about its eventual impact. That will inevitably produce billions of dollars in revenue for Biogen while allowing the company to continue collecting data on any positive impacts of the treatment on patients.\nHoping for a cure\nIt's precisely because so much is on the line for so many people that Biogen's Alzheimer's treatment generates such strong emotion. Nevertheless, everyone has to be hoping that Aduhelm will be able to prove itself once and for all and start providing relief for those who suffer from the disease.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":2248,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/117657812"}